Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 8/2/23 Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments 7/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 7/26/23 Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results 7/5/23 Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million 7/3/23 Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit 6/30/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6/22/23 Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy 5/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 5/24/23 Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001 5/12/23 Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 813 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 8/2/23 Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments 7/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 7/26/23 Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results 7/5/23 Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million 7/3/23 Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit 6/30/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 6/22/23 Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy 5/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 5/24/23 Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001 5/12/23 Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 813